๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

28 recruiting trials

for Refractory/Recurrent Peripheral T-cell Lymphoma

Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites๐Ÿ“ Scottsdale๐Ÿ“ Rochester Mayo Clinic ยท Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL NCT06966154Phase 1, Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: tislezumab, golidocitinib, Selinexor A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL NCT06855823Phase 1, Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Golicitinib combined with Pomadomide Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma NCT06151106Phase 21 site๐Ÿ“ Xiamen The First Affiliated Hospital of Xiamen University ยท Tests: Chidamide combined with Duvillisib Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT06810778Phase 1, Phase 21 site๐Ÿ“ Los Angeles Jonsson Comprehensive Cancer Center ยท Tests: Duvelisib, Venetoclax Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) NCT05833724Phase 26 sites๐Ÿ“ Kaohsiung City๐Ÿ“ Kaohsiung City๐Ÿ“ New Taipei City Great Novel Therapeutics Biotech & Medicals Corporation ยท Tests: Chidamide Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma NCT06909877Phase 1, Phase 21 site๐Ÿ“ Chengdu Haihe Biopharma Co., Ltd. ยท Tests: HH2853 Tablets Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site๐Ÿ“ Singapore National Cancer Centre, Singapore ยท Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. NCT07598578EARLY Phase 11 site๐Ÿ“ Suzhou Second Affiliated Hospital of Soochow University ยท Tests: Azacitidine (AZA) Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site๐Ÿ“ Shanghai Rong Tao ยท Tests: Tislelizumab, Zeprumetostat CD7 CAR-T Cells in T-cell Lymphoma/Leukemia NCT05620680NA1 site๐Ÿ“ Shenzhen Shenzhen University General Hospital ยท Tests: CD7 CAR-T cells Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma NCT07164560Phase 11 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Anti-TRBC1 CAR-T cells A Vaccine (VSV-hIFNฮฒ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma NCT03017820Phase 12 sites๐Ÿ“ Scottsdale๐Ÿ“ Rochester Mayo Clinic ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. NCT06393738Phase 121 sites๐Ÿ“ New Haven๐Ÿ“ Miami๐Ÿ“ Detroit Arvinas Inc. ยท Tests: ARV-393, Glofitamab Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma NCT06508463Phase 12 sites๐Ÿ“ Scottsdale๐Ÿ“ Rochester Mayo Clinic ยท Tests: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype NCT06522737Phase 344 sites๐Ÿ“ Ghent๐Ÿ“ Leuven๐Ÿ“ Prague SecuraBio ยท Tests: Duvelisib, Gemcitabine, Bendamustine A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL NCT06854653Phase 215 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ New Haven Prescient Therapeutics, Ltd. ยท Tests: PTX-100 Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma NCT05996185Phase 22 sites๐Ÿ“ New Haven๐Ÿ“ New York Yale University ยท Tests: Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma NCT03011814Phase 1, Phase 24 sites๐Ÿ“ Duarte๐Ÿ“ New York๐Ÿ“ Philadelphia City of Hope Medical Center ยท Tests: Durvalumab, Laboratory Biomarker Analysis, Lenalidomide Amping up With PemJAK NCT07283822Phase 21 site๐Ÿ“ New York Seda S. Tolu ยท Tests: Ruxolitinib, Pembrolizumab Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL NCT07058103Phase 21 site๐Ÿ“ Xuzhou The Affiliated Hospital of Xuzhou Medical University ยท Tests: tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology NCT06378190Phase 1, Phase 28 sites๐Ÿ“ Barcelona๐Ÿ“ L'Hospitalet de Llobregat๐Ÿ“ Madrid Instituto de Investigaciรณn Biomรฉdica de Salamanca ยท Tests: CAR-T cells therapy Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma NCT05313243Phase 22 sites๐Ÿ“ New Haven๐Ÿ“ Boston Yale University ยท Tests: Brentuximab vedotin, Pembrolizumab SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma NCT06122389Phase 31 site๐Ÿ“ Beijing Jiangsu HengRui Medicine Co., Ltd. ยท Tests: SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide Registry of Older Patients With Cancer NCT01137825n/a7 sites๐Ÿ“ Boone๐Ÿ“ Chapel Hill๐Ÿ“ Greenville UNC Lineberger Comprehensive Cancer Center Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma NCT07225985Phase 1, Phase 21 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: Bendamustine, Pralatrexate, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy